Antonio Jesús Ruiz Malagón

Dr. Antonio Jesús Ruiz Malagón

Digestive System Unit, Instituto de Investigación Biomédica de Málaga (IBIMA)-Plataforma Bionand, Málaga, Andalusia, Spain
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MSMaría Jesús Rodríguez Sojo
María Jesús Rodríguez Sojo
Antonio Jesús Ruiz MalagónAntonio Jesús Ruiz Malagón
Antonio Jesús Ruiz Malagón
Maria Elena Rodriguez-CabezasMaria Elena Rodriguez-Cabezas
Maria Elena Rodriguez-Cabezas
Julio GalvezJulio Galvez
Julio Galvez
Alba Rodríguez-NogalesAlba Rodríguez-Nogales
Alba Rodríguez-Nogales
Probiotics microorganisms exert their health-associated activities through some of the following general actions: competitive exclusion, enhancement of intestinal barrier function, production of bacteriocins, improvement of altered microbiota, and modulation of the immune response. Among them, Limosilactobacillus fermentum CECT5716 has become one of the most promising probiotics and it has been described to possess potential beneficial effects on inflammatory processes and immunological alterations. Different studies, preclinical and clinical trials, have evidenced its anti-inflammatory and immunomodulatory properties and elucidated the precise mechanisms of action involved in its beneficial effects. Therefore, the aim of this review is to provide an updated overview of the effect on host health, mechanisms, and future therapeutic approaches.

1 January 2020 in Food Research International
Verified
Journal Article
Closed access
PDPatricia Diez-Echave
Patricia Diez-Echave
TVTeresa Vezza
Teresa Vezza
Alba Rodríguez-NogalesAlba Rodríguez-Nogales
Alba Rodríguez-Nogales
Antonio Jesús Ruiz MalagónAntonio Jesús Ruiz Malagón
Antonio Jesús Ruiz Malagón
LHLaura Hidalgo-García
Laura Hidalgo-García
Julio GalvezJulio Galvez
Julio Galvez

11 August 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
Francisco Javier Leyva JimenezFrancisco Javier Leyva Jimenez
Francisco Javier Leyva Jimenez
Antonio Jesús Ruiz MalagónAntonio Jesús Ruiz Malagón
Antonio Jesús Ruiz Malagón
JTJose Alberto Molina Tijeras
Jose Alberto Molina Tijeras
PEPatricia Diez echave
Patricia Diez echave
TVTeresa Vezza
Teresa Vezza
Julio GalvezJulio Galvez
Julio Galvez
Increased levels of reactive oxygen species (ROS) and a low-grade chronic inflammation in multiple organs have been demonstrated in obesity. Morus alba leaves extracts (MAEs) have been used in traditional medicine as anti-inflammatory agents. In this work, the bioactive compounds of different genotypes of M. alba L. (Filipina, Valenciana Temprana, Kokuso, and Italia) were analyzed not only by reverse phase high performance liquid chromatography–electrospray ionization-time of flight-mass spectrometry (RP-HPLC-ESI-TOF-MS) and hydrophilic interaction chromatography–electrospray ionization-time of flight-mass spectrometry (HILIC-ESI-TOF-MS), but also screened for in vitro and in vivo antioxidant activity by means of DPPH• radical scavenging assay and Caenorhabditis elegans model. These MAEs were administered daily in a model of diet-induced obesity in mice. Filipina and Italia genotypes significantly reduced weight gain, the glycemic levels in high fat diet, as well as, levels of LDL-cholesterol and triglycerides. Filipina and Italia MAEs also reduced the expression of proinflammatory mediators such as Tnf-α, Il-1β, Il-6 and increased the levels of adiponectin and AMPK, which exert anti-inflammatory effects. Moreover, Italia genotype ameliorated the intestinal barrier function. In conclusion, Filipina and Italia methanolic extracts show the highest antioxidant and anti-inflammatory effect, due to the presence of compounds such as protocatechuic acid or quercetin-3-glucoside, and they could be developed as a complementary treatment for obesity and metabolic disorders.

6 March 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
MGMaría José García-Mansilla
María José García-Mansilla
MSMaría Jesús Rodríguez Sojo
María Jesús Rodríguez Sojo
ALAndreea Roxana Lista
Andreea Roxana Lista
CMCiskey Vanessa Ayala Mosqueda
Ciskey Vanessa Ayala Mosqueda
Antonio Jesús Ruiz MalagónAntonio Jesús Ruiz Malagón
Antonio Jesús Ruiz Malagón
MRMaria Jose Rodriguez-Sánchez
Maria Jose Rodriguez-Sánchez
The potential of microbial-derived antioxidants to modulate intestinal inflammation is increasingly recognized, which is especially important in inflammatory bowel diseases (IBD). Oxidative stress, a major contributor to chronic intestinal inflammation, is the result of an imbalance between the production of reactive oxygen species (ROS) and the body’s antioxidant defenses. This systematic review explores the role of microbial-derived antioxidants in alleviating IBD. Among the main findings are certain compounds, such as exopolysaccharides (EPS) and short-chain fatty acids (SCFAs), which have demonstrated their ability to neutralize ROS and strengthen the integrity of the intestinal barrier, thereby attenuating inflammatory responses. These antioxidants offer the dual benefit of mitigating oxidative stress and rebalancing the gut microbiota, which is often disrupted in IBD. Evidence from preclinical and clinical studies provides a better understanding of the mechanisms involved in the effects of these microbial antioxidants. Conventional treatments for IBD primarily focus on immune modulation. In this context, the integration of microbial-derived antioxidants could offer a complementary approach by addressing both oxidative damage and gut dysbiosis. Further research and clinical trials are essential to establish standardized treatment guidelines and clarify the long-term efficacy of these promising therapeutic agents.

28 May 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
Antonio Jesús Ruiz MalagónAntonio Jesús Ruiz Malagón
Antonio Jesús Ruiz Malagón
MSMaría Jesús Rodríguez Sojo
María Jesús Rodríguez Sojo
LHLaura Hidalgo-García
Laura Hidalgo-García
JTJose Alberto Molina Tijeras
Jose Alberto Molina Tijeras
FGFederico Garcia
Federico Garcia
Julio GalvezJulio Galvez
Julio Galvez
Nowadays, there is an increasing interest in alternative therapies in the treatment of metabolic syndrome that combine efficacy and safety profiles. Therefore, this study aimed to evaluate the effect of an extract of Thymus serpyllum, containing rosmarinic acid, on high-fat diet (HFD)-induced obesity mice, highlighting the impact of its antioxidant activity on the inflammatory status and gut dysbiosis. The extract was administered daily (50, 100 and 150 mg/kg) in HFD-fed mice. The treatment reduced body weight gain, glucose and lipid metabolic profiles. Moreover, the extract ameliorated the inflammatory status, with the c-Jun N-terminal kinases (JUNK) pathway being involved, and showed a significant antioxidant effect by the reduction of radical scavenging activity and the mitigation of lipid peroxidation. Moreover, the extract was able to modulate the altered gut microbiota, restoring microbial richness and diversity, and augmenting the counts of short-chain fatty acid producing bacteria, which have been associated with the maintenance of gut permeability and weight regulation. In conclusion, the antioxidant activity of Thymus serpyllum extract displayed a positive impact on obesity and its metabolic alterations, also reducing systemic inflammation. These effects may be mediated by modulation of the gut microbiota.

28 July 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
TVTeresa Vezza
Teresa Vezza
JMJosé Garrido Mesa
José Garrido Mesa
PEPatricia Diez echave
Patricia Diez echave
LHLaura Hidalgo-García
Laura Hidalgo-García
Antonio Jesús Ruiz MalagónAntonio Jesús Ruiz Malagón
Antonio Jesús Ruiz Malagón
Maria Elena Rodriguez-CabezasMaria Elena Rodriguez-Cabezas
Maria Elena Rodriguez-Cabezas
Background: Propyl propane thiosulfonate (PTSO) is an organosulfur compound from Allium spp. that has shown interesting antimicrobial properties and immunomodulatory effects in different experimental models. In this sense, our aim was to evaluate its effect on an experimental model of obesity, focusing on inflammatory and metabolic markers and the gut microbiota. Methods and results: Mice were fed a high-fat diet and orally treated with different doses of PTSO (0.1, 0.5 and 1 mg/kg/day) for 5 weeks. PTSO lessened the weight gain and improved the plasma markers associated with glucose and lipid metabolisms. PTSO also attenuated obesity-associated systemic inflammation, reducing the immune cell infiltration and, thus, the expression of pro-inflammatory cytokines in adipose and hepatic tissues (Il-1ẞ, Il-6, Tnf-α, Mcp-1, Jnk-1, Jnk-2, Leptin, Leptin R, Adiponectin, Ampk, Ppar-α, Ppar-γ, Glut-4 and Tlr-4) and improving the expression of different key elements for gut barrier integrity (Muc-2, Muc-3, Occludin, Zo-1 and Tff-3). Additionally, these effects were connected to a regulation of the gut microbiome, which was altered by the high-fat diet. Conclusion: Allium-derived PTSO can be considered a potential new tool for the treatment of metabolic syndrome.